{"id":"W2980391958","doi":"10.1182/blood.v122.21.2743.2743","title":"Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, ≥24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML)","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Discontinuation; Internal medicine; Adverse effect; Cohort; Nilotinib; Dasatinib; Neutropenia; Oncology; Imatinib; Surgery; Myeloid leukemia; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002622176,0.0008062099,0.001306486,0.0004334939,0.0003324682,0.0008254247,0.0004701743,0.0004915894,0.002179244],"category_scores_gemma":[0.001645302,0.0002749698,0.002389644,0.000404052,0.0003306154,0.0005471916,0.0003712932,0.0008970508,0.000406507],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008698675,"about_ca_system_score_gemma":0.0007341568,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005229418,"about_ca_topic_score_gemma":0.001263426,"domain_scores_codex":[0.9991791,0.0003095753,0.00007410892,0.0001886441,0.0001062691,0.0001423591],"domain_scores_gemma":[0.9984673,0.000307889,0.0004807982,0.0001598086,0.0001401243,0.000444213],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6734353,0.01064474,0.178282,0.0005507008,0.004316665,0.000517566,0.0002845689,0.003107929,0.04005175,0.000186177,0.002745213,0.08587746],"study_design_scores_gemma":[0.08300945,0.3389608,0.5575324,0.00005171691,0.002989329,0.0008038759,0.0001409991,0.002451897,0.008933624,0.0002048731,0.004852863,0.00006824862],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962985,0.0006735826,0.0002549679,0.00006672188,0.00001663877,0.0004845872,0.001451213,0.00002160492,0.0007322531],"genre_scores_gemma":[0.9955533,0.0001245799,0.000360806,0.00009285507,0.00003547706,0.0003433358,0.002998517,0.00000628768,0.0004848532],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002622176,"threshold_uncertainty_score":0.01386756,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01385439552640092,"score_gpt":0.2597159242319458,"score_spread":0.2458615287055449,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}